MA52667B1 - Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie - Google Patents

Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Info

Publication number
MA52667B1
MA52667B1 MA52667A MA52667A MA52667B1 MA 52667 B1 MA52667 B1 MA 52667B1 MA 52667 A MA52667 A MA 52667A MA 52667 A MA52667 A MA 52667A MA 52667 B1 MA52667 B1 MA 52667B1
Authority
MA
Morocco
Prior art keywords
methods
tils
immunotherapy
improved
infiltrating lymphocytes
Prior art date
Application number
MA52667A
Other languages
English (en)
Other versions
MA52667A (fr
Inventor
Seth Wardell
James Bender
Original Assignee
Iovance Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/940,901 external-priority patent/US10918666B2/en
Application filed by Iovance Biotherapeutics, Inc. filed Critical Iovance Biotherapeutics, Inc.
Publication of MA52667A publication Critical patent/MA52667A/fr
Publication of MA52667B1 publication Critical patent/MA52667B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/142—Apparatus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)

Abstract

La présente invention concerne des procédés améliorés et/ou raccourcis pour étendre les TIL et produire des populations thérapeutiques de TIL, y compris de nouveaux procédés pour étendre les populations de TIL dans un système fermé qui conduisent à une efficacité améliorée, à un phénotype amélioré et à une meilleure santé métabolique des TIL dans une période de temps plus courte, tout en permettant une contamination microbienne réduite ainsi que des coûts réduits. De tels TIL trouvent une utilisation dans des schémas thérapeutiques. 
MA52667A 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie MA52667B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/940,901 US10918666B2 (en) 2017-03-29 2018-03-29 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP18745741.1A EP3775165B1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
PCT/US2018/040474 WO2019190579A1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Publications (2)

Publication Number Publication Date
MA52667A MA52667A (fr) 2021-02-17
MA52667B1 true MA52667B1 (fr) 2024-07-31

Family

ID=63013105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52667A MA52667B1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Country Status (24)

Country Link
EP (2) EP3775165B1 (fr)
KR (2) KR20200138329A (fr)
CN (1) CN112513254A (fr)
AU (2) AU2018415814B2 (fr)
BR (1) BR112020019496A2 (fr)
CA (1) CA3094957A1 (fr)
DK (1) DK3775165T3 (fr)
EA (1) EA202092319A1 (fr)
ES (1) ES2982509T3 (fr)
FI (1) FI3775165T3 (fr)
HR (1) HRP20240850T1 (fr)
HU (1) HUE068082T2 (fr)
IL (1) IL277592A (fr)
LT (1) LT3775165T (fr)
MA (1) MA52667B1 (fr)
MD (1) MD3775165T2 (fr)
MX (1) MX2020010264A (fr)
PL (1) PL3775165T3 (fr)
PT (1) PT3775165T (fr)
RS (1) RS65674B1 (fr)
SG (1) SG11202009170UA (fr)
SI (1) SI3775165T1 (fr)
SM (1) SMT202400287T1 (fr)
WO (1) WO2019190579A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3765094A4 (fr) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Compositions de régulation génique et procédés pour améliorer l'immunothérapie
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021167908A1 (fr) * 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Procédés d'expansion de lymphocytes infiltrant les tumeurs et leur utilisation
JP7840569B2 (ja) 2020-02-17 2026-04-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒト４－１ｂｂアゴニスト抗体およびその使用方法
WO2021222479A1 (fr) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Procédés de culture de cellules
WO2022111571A1 (fr) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 Milieu de culture de lymphocytes d'infiltration de tumeurs et son application
EP4263807A2 (fr) * 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Traitement de lymphocytes infiltrant les tumeurs
CA3205464A1 (fr) * 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Traitement de lymphocytes infiltrant les tumeurs
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
KR102666931B1 (ko) * 2021-03-30 2024-05-20 주식회사 네오젠티씨 면역세포 조성물을 생산하는 방법
WO2022263673A1 (fr) * 2021-06-17 2022-12-22 CBio A/S Procédé en plusieurs étapes pour cultiver des lymphocytes infiltrant les tumeurs pour un usage thérapeutique
CA3253072A1 (fr) * 2022-05-11 2023-11-16 Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigacao Da Procédé de préparation et de multiplication d'une population de cellules immunitaires pour la thérapie anticancéreuse, test d'activité biologique pour la reconnaissance des tumeurs, préparation de vaccins biologiques et cible épitope pour les anticorps
IL325907A (en) 2023-07-13 2026-03-01 Iovance Biotherapeutics Inc Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025083398A1 (fr) 2023-10-16 2025-04-24 Cell Therapy Catapult Limited Co-culture
CN120888499A (zh) * 2025-09-29 2025-11-04 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种肿瘤浸润淋巴细胞的扩增培养方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
DE69624436T2 (de) 1995-04-08 2003-08-28 Lg Chemical Ltd., Seoul/Soul Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
EP2316490A3 (fr) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methodes et compositions pour améliorer l'administration de molécules bioactives
JP2006500921A (ja) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー ヒト４−１ｂｂに対するヒト化抗体
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1894940A1 (fr) 2006-08-28 2008-03-05 Apogenix GmbH Protéines de fusion de la superfamille TNF
EP2484691B1 (fr) 2007-07-10 2016-01-13 Apogenix GmbH Protéines de fusion collectines de la superfamille des TNF
EP2310409A2 (fr) 2008-06-17 2011-04-20 Apogenix GmbH Récepteurs multimériques tnf
PL2604693T3 (pl) 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
WO2010078966A1 (fr) 2009-01-09 2010-07-15 Apogenix Gmbh Protéines de fusion formant des trimères
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2011072088A2 (fr) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Procédés améliorés de culture cellulaire pour thérapie cellulaire adoptive
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2012177788A1 (fr) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulateurs de 4-1bb et réponses immunitaires
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
CN104379727A (zh) 2012-05-18 2015-02-25 威尔逊沃夫制造公司 改进的用于过继细胞治疗的细胞培养方法
CN110241086A (zh) 2012-06-11 2019-09-17 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
WO2014133567A1 (fr) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de production de populations enrichies de lymphocytes t réactifs à une tumeur à partir d'une tumeur
SG10201705494YA (en) 2013-06-24 2017-08-30 Wolf Wilson Mfg Corp Closed system device and methods for gas permeable cell culture process
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
ES2980788T3 (es) * 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
UA123821C2 (uk) 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
FR3040396A1 (fr) * 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي

Also Published As

Publication number Publication date
AU2018415814A1 (en) 2020-10-22
EP3775165A1 (fr) 2021-02-17
SG11202009170UA (en) 2020-10-29
MX2020010264A (es) 2020-11-06
PT3775165T (pt) 2024-07-17
ES2982509T3 (es) 2024-10-16
DK3775165T3 (da) 2024-07-08
EA202092319A1 (ru) 2021-03-04
BR112020019496A2 (pt) 2021-01-12
EP4386080A3 (fr) 2024-12-04
FI3775165T3 (fi) 2024-07-01
IL277592A (en) 2020-11-30
RS65674B1 (sr) 2024-07-31
CA3094957A1 (fr) 2019-10-03
MD3775165T2 (ro) 2024-09-30
EP3775165B1 (fr) 2024-03-27
SMT202400287T1 (it) 2024-09-16
MA52667A (fr) 2021-02-17
CN112513254A (zh) 2021-03-16
LT3775165T (lt) 2024-07-10
KR20250137200A (ko) 2025-09-17
AU2025256177A1 (en) 2025-11-13
HUE068082T2 (hu) 2024-12-28
KR20200138329A (ko) 2020-12-09
AU2018415814B2 (en) 2025-08-14
HRP20240850T1 (hr) 2024-09-27
PL3775165T3 (pl) 2024-08-19
EP4386080A2 (fr) 2024-06-19
WO2019190579A1 (fr) 2019-10-03
SI3775165T1 (sl) 2024-09-30

Similar Documents

Publication Publication Date Title
MA68856B1 (fr) Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
EA202092319A1 (ru) Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MX2020000916A (es) Anticuerpos anti-cd8 y usos de estos.
WO2019036432A8 (fr) Récepteurs olfactifs ectopiques et leurs utilisations
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
WO2018052464A8 (fr) Procédés et systèmes pour essais multiplex
AU2018262331A1 (en) Methods for trapping and barcoding discrete biological units in hydrogel
MA38526A1 (fr) Nouvelle souche bactérienne de lysobacter capsici et ses utilisations
FR3014198B1 (fr) Procede d'isolement d'exosomes
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
ZA202003408B (en) A microcapsule for detecting and/or quantitating an analyte in a sample
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
PL2129391T3 (pl) Metoda diagnostyczna